Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.
Jaroszewicz J, Pawłowska M, Simon K, Zarębska-Michaluk D, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Janczewska E, Paluch K, Dybowska D, Buczyńska I, Czauż-Andrzejuk A, Berak H, Krygier R, Piasecki M, Dobracka B, Citko J, Piekarska A, Socha Ł, Deroń Z, Tronina O, Laurans Ł, Białkowska J, Tomasiewicz K, Halota W, Flisiak R.
Jaroszewicz J, et al.
Expert Rev Anti Infect Ther. 2020 Oct;18(10):1045-1054. doi: 10.1080/14787210.2020.1782189. Epub 2020 Jun 27.
Expert Rev Anti Infect Ther. 2020.
PMID: 32538232